AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ATHR
Report Date: 2026-04-06
Full Report: https://amaly.io/stock/ATHR

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Athira Pharma Inc. (ATHR) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases such as Alzheimer's. This report evaluates its Shariah compliance through financial screening, business activity analysis, ESG factors, and index inclusion status. The core business is permissible, with low debt and liquidity ratios, but the interest income ratio of 8.42% exceeds the 5% threshold, leading to exclusion from major Shariah indices. Regional variations exist, with compliance in Malaysia and Indonesia but non-compliance under AAOIFI and GCC standards. Investors should consider purification and monitor financial evolution for potential future compliance.

Primary Compliance Concerns:
- Interest income ratio of 8.42% exceeds 5% threshold across standards
- Exclusion from all major Shariah-compliant indices due to impure income

Purification Requirement: 8.42%
Index Inclusion: Excluded from S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, and Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 0.0%
Liquidity Ratio: 0.0%
Interest Income Ratio: 0.0%
Purification Required: 8.42%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2021 to FY 2025
Data Retrieved: 2026-02-27T12:00:00Z

---
Full interactive report: https://amaly.io/stock/ATHR
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.